Glioblastoma

P3, N=306, Suspended, NRG Oncology | Recruiting --> Suspended

P1, N=40, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting

P2, N=120, Recruiting, Insel Gruppe AG, University Hospital Bern | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028

P2, N=36, Suspended, Mayo Clinic | Not yet recruiting --> Suspended

These findings suggest that CSF cfDNA effectively represents the genetic profile of gliomas and serves as a sensitive measure for surgical resection efficacy and patient prognosis, highlighting its potential as a non-invasive biomarker for enhancing post-operative management in glioma patients.

Mitochondrial dysfunction mediated by MTHFD2 in macrophages plays a key role in GBM progression and immune heterogeneity. MTHFD2 represents a potential diagnostic biomarker and therapeutic target for modulating GBM immune infiltration.

Glioblastoma (GB) is highly malignant with a median survival of 14 months despite conventional treatments like surgery, radiotherapy, and temozolomide...In addition, studies showed that gut-derived metabolites, including short-chain fatty acids, modulate immune responses and support blood-brain barrier integrity by regulating inflammatory signaling and tight junction proteins. Future GB research should prioritize clinical trials, mechanistic studies, and interventional strategies like fecal microbiota transplantation and probiotics to enhance ICI efficacy.

Furthermore, miR-93-5p was validated as a critical gene, with its disruption leading to significant reductions in GBM cell proliferation, migration, and invasion. The novel CRM signature enhances the prognostic landscape for patients with LGG, offering a new framework for evaluating immunotherapeutic efficacy.

The inhibition of OPN increased GBM sensitivity to temozolomide (TMZ) in orthotopic models. This study revealed the potential mechanism by which hypoxia-induced OPN+ GAMs promote the mesenchymal transition in GBM cells and demonstrated the therapeutic potential of targeting OPN to enhance TMZ treatment effectiveness.

A2b11-liposomes loaded with sodium fluorescein (FLA) and A2b11-liposomes loaded with temozolomide (TLA) were evaluated for their anti-GBM effects...The A2b11 peptide-modified liposomal system developed in this study represents a promising platform for GBM-targeted therapy. Further research and development of this platform could lay the groundwork for its future clinical application.

Ingenuity Pathway Analysis (IPA) revealed that miR-16-5p and other miRNAs with seed AGCAGCA formed the largest interaction network in GBM, while disease enrichment analysis using Database for Annotation, Visualization, and Integrated Discovery (DAVID) confirmed that the 1000 predicted mRNA targets of DE-miRNAs in GBM were disease relevant. Collectively, these findings identify a robust panel of CSF-derived miRNAs capable of distinguishing IDH-mutant gliomas, GBM, and non-tumor states, supporting the potential of EV-miRNAs as minimally invasive biomarkers for the molecular characterization of diffuse gliomas.

Clones were injected subcutaneously or intracranially with or without anti-PD-1/anti-CTLA4 and dexamethasone...Rather, rejection depended on increased secretion of pro-inflammatory chemokines. Msh2 and Mlh1 loss was not equivalent, suggesting that additional studies are needed to elucidate germline and somatic mismatch repair gene-specific immune alterations.